Home > Oncology > ASCO 2020 > Paediatric Cancer > Sustained improvements in quality of life with larotrectinib

Sustained improvements in quality of life with larotrectinib

Expert
Prof. Shivaani Kummar, Stanford School of Medicine, CA, USA
Conference
ASCO 2020
Trial
Phase 2 NAVIGATE, phase 1/2 SCOUT
In the majority of adults, children, and infants with TRK-fusion cancer, treatment with larotrectinib induces rapid, sustained, and clinically meaningful improvements in quality of life. Larotrectinib is a highly selective TRK inhibitor that is approved to treat adult and paediatric patients with solid tumours harbouring an NTRK gene-fusion. In clinical trials, larotrectinib demonstrated a 79% objective response rate and over 35 months median duration of response, regardless of tumour type and age [1]. The drug was well tolerated with mainly grade 1 or 2 adverse events. To get more insight in the efficacy of larotrectinib on quality of life, quality of life outcomes were analysed from an expanded dataset of adults, children, and infants with TRK fusion cancer treated with larotrectinib in 2 ongoing trials: a phase 2 basket trial in adults and adolescents (NAVIGATE) and a single-arm phase 1/2 trial in paediatric patients (SCOUT). Pa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on